Korsana Biosciences

Company

Related News

Kos Fund Closes at $123M, ParcelBio Launches with $13M, Korsana Emerges with $175M

Jun 14, 2026

Three biotech companies announce significant funding: Korsana Biosciences secures $175 million for neurodegenerative therapies, Kos Biotechnology Partners closes a $123 million life sciences fund, and ParcelBio launches with $13 million to advance mRNA medicines.

Korsana Biosciences Emerges With $175M to Develop Next-Generation Alzheimer's Therapy

Feb 19, 2026

Korsana Biosciences launched from stealth with $175 million in funding to advance KRSA-028, a monoclonal antibody targeting amyloid beta plaques in Alzheimer's disease using a blood-brain barrier shuttle technology.